The study is being conducted to evaluate the effects of different dosage regimen on the pharmacokinetics of HRS9531 tablets in healthy subjects.
Ability to understand the trial procedures, be able and willing to provide a written informed consent.
Male subject aged 18-55 years (both inclusive) at the time of signing informed consent.
Body weight ≥ 50.0 kg, body mass index (BMI) of 23.0-35.0 kg/m² (both inclusive) at screening.
Weight change does not exceed 5 kg within 3 months before screening.
Known or suspected hypersensitivity to trial product(s) or related products.
With previous major organ diseases, including but not limited to neuropsychiatric, cardiovascular, digestive, respiratory, urinary, endocrine, blood, immune and other diseases, are judged by researchers to be unsuitable for the study.
Abnormal and clinically significant blood pressure at screening.
History of significant gastrointestinal diseases or related symptoms (e.g., nausea, vomiting, heartburn, or diarrhea), conditions affecting gastric emptying (e.g., pyloric stenosis), or previous gastrointestinal surgery (excluding polypectomy and appendectomy), or acute diarrhea or constipation within 7 days before randomization.
Parallel
HRS9531 tablets
DrugHRS9531 tablets.
AUCtau
Area under the HRS9531 tablets concentration curve from time 0-24 hours after the 10th dosing
Tmax
Time to maximum plasma concentration
Cmax
The maximum plasma concentration
t1/2
Terminal half-life
Incidence and severity of adverse events
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
